

Cyclin Dependent Kinase 6 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/CB62AEF39CEDEN.html>

Date: May 2020

Pages: 176

Price: US\$ 3,500.00 (Single User License)

ID: CB62AEF39CEDEN

Abstracts

Cyclin Dependent Kinase 6 - Pipeline Review, H1 2020

SUMMARY

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 31 molecules. Out of which approximately 30 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 6 – Pipeline Review, H1 2020, outlays comprehensive information on the Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) – Cell division protein kinase 6 (CDK6) is an enzyme encoded by the CDK6 gene. It is involved in initiation and maintenance of cell cycle exit during cell differentiation, prevents cell proliferation and regulates negatively cell differentiation. It is required during thymocyte development. It promotes the production of newborn neurons, probably by modulating G1 length, changes in the actin cytoskeleton including loss of stress fibers, and enhanced motility during cell differentiation. It prevents myeloid differentiation by interfering with RUNX1 and reducing its transcription transactivation-activity. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 9, 2, 8 and 4 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease,

Cardiovascular, Metabolic Disorders and Toxicology which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Colorectal Cancer, Metastatic Colorectal Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Endometrial Cancer, Fallopian Tube Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Peritoneal Cancer, Bladder Cancer, Colon Cancer, Dedifferentiated Liposarcoma, Epithelial Ovarian Cancer, Esophageal Cancer, Head And Neck Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Leukemia, Liposarcoma, Lung Cancer, Lymphoma, Metastatic Melanoma, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Ovarian Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Pediatric Diffuse Intrinsic Pontine Glioma, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, AIDS - Related Cancer, Anaplastic Oligoastrocytoma, Astrocytoma, Bile Duct Cancer (Cholangiocarcinoma), Brain Cancer, Brain Tumor, Cervical Cancer, Chemotherapy Induced Myelosuppression, Chordoma, Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Ductal Carcinoma In Situ, Duodenal Cancer, Ependymoma, Epstein–Barr Virus (HHV-4) Infections, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Follicular Lymphoma, High-Grade Glioma, Hormone Sensitive Breast Cancer, Human Immunodeficiency Virus (HIV) Infections (AIDS), Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Malignant Mesothelioma, Marginal Zone B-cell Lymphoma, Medulloblastoma, Melanoma, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Multiple Myeloma (Kahler Disease), Nonmelanomatous Skin Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Primary CNS Lymphoma, Pulmonary Arterial Hypertension, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transitional Cell Cancer (Urothelial Cell Cancer), Type 2 Diabetes and Well Differentiated Liposarcoma.

Note: Certain content/sections in the pipeline guide may be removed or altered based

on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

The report reviews Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects

The report assesses Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Overview

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Development

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Therapeutics Assessment

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Companies Involved in Therapeutics

Development

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Drug Profiles

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Dormant Products

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Discontinued Products

Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1)
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Beta Pharma Inc, H1 2020
Pipeline by Betta Pharmaceuticals Co Ltd, H1 2020
Pipeline by CStone Pharmaceuticals Co Ltd, H1 2020
Pipeline by Eli Lilly and Co, H1 2020
Pipeline by ESSA Pharma Inc, H1 2020
Pipeline by Fochon Pharmaceutical Ltd, H1 2020
Pipeline by G1 Therapeutics Inc, H1 2020
Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, H1 2020
Pipeline by HEC Pharm Co Ltd, H1 2020
Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2020
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020

Pipeline by MEI Pharma Inc, H1 2020

Pipeline by Novartis AG, H1 2020

Pipeline by Onconova Therapeutics Inc, H1 2020

Pipeline by Pfizer Inc, H1 2020

Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H1 2020

Pipeline by Shanghai Haihe Biopharma Co Ltd, H1 2020

Pipeline by Shanghai Haishi Biopharmaceutical Co Ltd, H1 2020

Pipeline by Shanghai Pharmaceutical Group Co Ltd, H1 2020

Pipeline by SignalRx Pharmaceuticals Inc, H1 2020

Pipeline by Sihuan Pharmaceutical Holdings Group Ltd, H1 2020

Pipeline by Sino Biopharmaceutical Ltd, H1 2020

Pipeline by Tetranov International Inc, H1 2020

Pipeline by ViroStatics SRL, H1 2020

Dormant Products, H1 2020

Dormant Products, H1 2020 (Contd..1), H1 2020

Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Beta Pharma Inc
Betta Pharmaceuticals Co Ltd
CStone Pharmaceuticals Co Ltd
Eli Lilly and Co
ESSA Pharma Inc
Fochon Pharmaceutical Ltd
G1 Therapeutics Inc
Guangzhou BeBetter Medicine Technology Co Ltd
HEC Pharm Co Ltd
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
MEI Pharma Inc
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Rizen (Suzhou) Biosciences Co Ltd
Shanghai Haihe Biopharma Co Ltd
Shanghai Haishi Biopharmaceutical Co Ltd
Shanghai Pharmaceutical Group Co Ltd
SignalRx Pharmaceuticals Inc
Sihuan Pharmaceutical Holdings Group Ltd
Sino Biopharmaceutical Ltd
Tetranov International Inc
ViroStatics SRL

I would like to order

Product name: Cyclin Dependent Kinase 6 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/CB62AEF39CEDEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CB62AEF39CEDEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970